NCT03071679 is a Phase 1 clinical trial of Omiganan in Healthy, sponsored by Maruho Co., Ltd..

Who is sponsoring NCT03071679?

NCT03071679 is sponsored by Maruho Co., Ltd..

What drugs are being tested in NCT03071679?

Interventions in NCT03071679: Omiganan, Imiquimod, Omiganan 1% and Imiquimod, Omiganan 2.5% and Imiquimod, Placebo.

Is NCT03071679 still recruiting?

NCT03071679 is currently completed. Last updated 22 May 2017.

Last reviewed 2017-05-22 · How we verify

NCT03071679

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Topical Challenge With Omiganan and Imiquimod in Healthy Volunteers

Completed Phase 1 Last updated 22 May 2017

What this trial tests

Phase 1 trial testing Omiganan in Healthy in 16 participants. Completed in 7 March 2017.

Timeline

6 February 2017

Primary endpoint
7 March 2017

7 March 2017

Quick facts

Lead sponsor	Maruho Co., Ltd.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	factorial
Masking	quadruple
Primary purpose	other
Enrollment	16
Start date	6 February 2017
Primary completion	7 March 2017
Estimated completion	7 March 2017
Sites	1 location across Netherlands

Drugs / interventions tested

Omiganan — full drug profile →
Imiquimod (IMIQUIMOD) — full drug profile →
Omiganan 1% and Imiquimod — full drug profile →
Omiganan 2.5% and Imiquimod — full drug profile →
Placebo

Conditions studied

Healthy — all drugs for Healthy →

Sponsor

Maruho Co., Ltd. — full company profile →

Who can join

Adults 18 to 45, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study has a randomized, evaluator-blinded, vehicle- controlled study to assess the pharmacodynamics of omiganan and omiganan with imiquimod in healthy volunteers.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

DRAMP 2.0, an updated data repository of antimicrobial peptides.
Kang X, Dong F, Shi C, Liu S, et al · · 2019 · cited 230× · PMID 31409791 · DOI 10.1038/s41597-019-0154-y
Strategies in Translating the Therapeutic Potentials of Host Defense Peptides.
Ting DSJ, Beuerman RW, Dua HS, Lakshminarayanan R, et al · · 2020 · cited 72× · PMID 32528474 · DOI 10.3389/fimmu.2020.00983
Pattern recognition receptors: function, regulation and therapeutic potential.
Chen R, Zou J, Chen J, Zhong X, et al · · 2025 · cited 53× · PMID 40640149 · DOI 10.1038/s41392-025-02264-1
Shaping the Future of Antimicrobial Therapy: Harnessing the Power of Antimicrobial Peptides in Biomedical Applications.
Tripathi AK, Singh J, Trivedi R, Ranade P. · · 2023 · cited 18× · PMID 37998108 · DOI 10.3390/jfb14110539

Verify or expand the search:

Other trials of Omiganan

Trials testing the same drug.

NCT03091426 — Pharmacodynamics of Omiganan BID in Patients With Atopic Dermatitis · Phase 2 · completed

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Other Maruho Co., Ltd. trials

Trials by the same sponsor.

NCT05214794 — An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Systemic Sclerosis · Phase 2 · completed
NCT03259620 — A Study to Evaluate the Safety and Efficacy of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous · Phase 3 · completed
NCT03334240 — ICVT in HPV-induced Genital Lesions of Immunocompromised and Immunocompetent Patients · Phase 2 · terminated
NCT03091426 — Pharmacodynamics of Omiganan BID in Patients With Atopic Dermatitis · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03071679 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Maruho Co., Ltd.
Last refreshed: 22 May 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03071679.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing